通过使用孟德尔随机化分析循环炎症蛋白来识别阿尔茨海默病的可用药物标
Hongliang An1, Jianhong Gu2, Taiping Li3
1Department of Pharmacy, Nanjing Meishan Hospital, Nanjing, China.
Brain and behavior
|August 27, 2025
概括
这项研究使用孟德尔随机化发现五种炎症蛋白TSLP,S100A12,CD244,CCL4和MMP1是阿尔茨海默病 (AD) 的潜在可用药物标. 在未来的阿尔茨海默氏症治疗中,
科学领域:
- 遗传学
- 神经科学
- 药理学
背景情况:
- 阿尔茨海默氏症 (AD) 是一个全球性的健康挑战.
- 确定新的治疗点对于有效的阿尔茨海默病治疗至关重要.
- 循环炎症蛋白质越来越多地被认为是AD的病原体.
研究的目的:
- 通过分析循环炎症蛋白来确定阿尔茨海默病 (AD) 的可用药物标.
- 使用孟德尔随机化 (MR) 研究炎症蛋白与AD风险之间的因果关系.
主要方法:
- 对91个循环炎症蛋白和AD进行了两样MR分析.
- 逆方差加权 (IVW) 模型是主要方法,加权中位数 (WM) 和MR- Egger用于敏感性分析.
- 使用ChEMBL和DGIdb数据库进行贝叶斯定位和基因药物相互作用分析.
主要成果:
- 八种炎症蛋白与阿尔茨海默病风险有显著关联.
- 其中五种蛋白TSLP,S100A12,CD244,CCL4和MMP1被确定为可用药物的标.
- MMP1和CCL4在前额叶皮层表现出最强的局部化证据,这表明在阿尔茨海默病中起因作用.
结论:
- 基因决定的TSLP,S100A12,CD244,CCL4和MMP1的循环水平会对AD风险产生因果影响.
- 这五种蛋白质被提名为阿尔茨海默病的潜在治疗点.
- MMP1和CCL4是进一步机制研究和临床验证的优先候选者.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
